← Back to All Filings

Astera Labs ($ALAB) CFO Receives Equity Compensation Grant

Low SignificanceFebruary 10, 2026 at 6:55:05 PM EST

Astera Labs, Inc.

$ALAB4CIK: 0001736297

Subscribe to track ALAB

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Astera Labs ($ALAB) CFO Receives Equity Compensation Grant

Company: Astera Labs, Inc. (ALAB) Form: 4 | Filed: 2026/02/10 Significance: Low

Insider: Tate Michael Truett Title: Chief Financial Officer | Relationship: Officer

Transaction: • Type: Grant (RSU Award) • Shares: 11,787 • Price: $0.00 • Value: $0 • Owned After: 654,365 (Direct & Indirect)

Key Insight: This is a routine equity compensation grant to the CFO, representing a negligible 0.007% of total shares outstanding.

Market Context: Such grants are standard practice for executive compensation in the tech industry to align insider interests with shareholder value over the long term.

Comprehensive Analysis

SEC Filing Analysis: Astera Labs, Inc. (ALAB)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Financial Officer of Astera Labs received a routine grant of Restricted Stock Units (RSUs) as part of their compensation package.
  • Market Impact: Neutral. This transaction is a non-cash, pre-planned compensation event and does not reflect new market sentiment from the insider.

Company Information

FieldValue
CompanyAstera Labs, Inc.
Ticker SymbolALAB
CIK0001736297
IndustrySemiconductors & Related Devices

Insider Information

FieldValue
NameTate Michael Truett
CIK0001399546
Title/PositionChief Financial Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2026-02-06
Transaction CodeA (Award)
Security TypeCommon Stock (via RSUs)
Shares Involved11,787
Price Per Share$0.00
Total Value$0
Shares Owned After204,084 (Directly) & 450,281 (Indirectly)
Ownership TypeDirect & Indirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.0%
Shares Transacted11,787
% of Shares Outstanding0.007%
Post-Transaction Ownership654,365 shares (0.387% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The transaction has no monetary value and is therefore immaterial against Astera Labs' $28.69 billion market capitalization.
  • Ownership Concentration: The CFO's total post-transaction ownership remains modest at 0.387% of shares outstanding, indicating no significant concentration of control.
  • Dilution Impact: The issuance of 11,787 shares represents a minimal dilution of 0.007% to existing shareholders, which is a routine and expected part of corporate compensation strategies.
  • Transaction Significance: The significance is low. This is a standard, non-market transaction intended as long-term incentive compensation, not an active investment decision by the insider.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: Equity grants are a common form of executive compensation and are not indicative of an insider's short-term outlook on the company's stock. The market generally does not react to such filings.

Volume & Sentiment

  • Expected Volume Impact: None. This was not an open-market transaction and does not affect trading volume.
  • Sentiment Indicator: Neutral. The filing confirms standard corporate governance practices regarding executive pay.

Additional Context

Transaction Notes

  • Special Circumstances: The filing notes that these shares are Restricted Stock Units (RSUs) granted under the company's 2024 Stock Option and Incentive Plan. The RSUs vest over time, with 25% vesting in one year and the remainder quarterly thereafter, contingent on continued service. This structure is designed to retain key executives.
Topics:#SECFiling#InsiderTrading#AsteraLabs#ALAB#Form4#EquityGrant#CFO#StockMarket#TechStocks

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.